Objective： This work aimed to study the inhibitory effect and the related mechanism of metformin （MET） on the proliferation of human hepatoma HepG2 cells. Methods： Human hepatoma HepG2 cells were treated with MET ...Objective： This work aimed to study the inhibitory effect and the related mechanism of metformin （MET） on the proliferation of human hepatoma HepG2 cells. Methods： Human hepatoma HepG2 cells were treated with MET （0, 2, 10, and 50 mM）. The inhibitory effect of MET on the proliferation of HepG2 cells was determined by MTT method. The apoptosis of HepG2 cells was detected by flow cytornetry. The expression of cyclin D1 in HepG2 cells was examined by Western blot. ROS-DHE fluorescence probe was used to stain the reactive oxygen species （ROS） generated by HepG2 cells after treat- ment. Results： MET could inhibit the proliferation of HepG2 cells in a dose and time dependent manner. MET promoted the apoptosis of HepG2 cells. In addition, MET suppressed the expression of cell cycle protein cyclin D1 and induced the produc- tion of ROS in HepG2 cells. Conclusion： MET can inhibit the proliferation of human hepatoma HepG2 cells and induce cell apoptosis. Meanwhile, MET has the ability to decrease the expression of cyclin D1 and induce ROS generation, which may be involved in the mechanism of inhibiting hepatoma cells proliferation.展开更多
目的:探讨舒尼替尼诱导人肝癌HepG2细胞表达的自然杀伤细胞2族成员D配体(natural killer group 2 member D ligands,NKG2DLs)与核因子kappa B(nuclear factor B kappa,NF-κB)信号通路之间的相互作用。方法:常规体外培养HepG2细胞,利用...目的:探讨舒尼替尼诱导人肝癌HepG2细胞表达的自然杀伤细胞2族成员D配体(natural killer group 2 member D ligands,NKG2DLs)与核因子kappa B(nuclear factor B kappa,NF-κB)信号通路之间的相互作用。方法:常规体外培养HepG2细胞,利用实时荧光定量PCR检测1μmol/L舒尼替尼处理HepG2细胞24 h前后NF-κB基因家族成员mRNA的表达情况,利用计算机辅助设计并合成NF-κB1、NF-κB2和Rel B siRNA引物,通过脂质体法将目的基因siRNA转染于HepG2细胞,荧光显微镜观察转染情况,实时荧光定量PCR检测干扰效率,Western blotting检测siRNA转染前后He G2细胞内NF-κB1、NF-κB2和Rel B蛋白表达,流式细胞术检测siRNA前后HepG2细胞NKG2DLs表达率。结果:实时荧光定量PCR结果显示,舒尼替尼处理HepG2细胞后,NF-κB1、NF-κB2和Rel B mRNA表达水平升高,主要以NF-κB2 mRNA和Rel B mRNA升高为主。荧光显微镜观测siRNA转染后HepG2细胞红色荧光表达率约为60%,干扰效率达95%以上。siRNA转染后HepG2细胞内NF-κB1、NF-κB2和Rel B蛋白表达水平明显下降,siRNA转染+药物组NKG2DLs表达率明显低于药物处理组(P<0.05)。结论:首次揭示了舒尼替尼通过NF-κB旁路途径诱导肿瘤细胞表达NKG2DLs。展开更多
文摘Objective： This work aimed to study the inhibitory effect and the related mechanism of metformin （MET） on the proliferation of human hepatoma HepG2 cells. Methods： Human hepatoma HepG2 cells were treated with MET （0, 2, 10, and 50 mM）. The inhibitory effect of MET on the proliferation of HepG2 cells was determined by MTT method. The apoptosis of HepG2 cells was detected by flow cytornetry. The expression of cyclin D1 in HepG2 cells was examined by Western blot. ROS-DHE fluorescence probe was used to stain the reactive oxygen species （ROS） generated by HepG2 cells after treat- ment. Results： MET could inhibit the proliferation of HepG2 cells in a dose and time dependent manner. MET promoted the apoptosis of HepG2 cells. In addition, MET suppressed the expression of cell cycle protein cyclin D1 and induced the produc- tion of ROS in HepG2 cells. Conclusion： MET can inhibit the proliferation of human hepatoma HepG2 cells and induce cell apoptosis. Meanwhile, MET has the ability to decrease the expression of cyclin D1 and induce ROS generation, which may be involved in the mechanism of inhibiting hepatoma cells proliferation.
文摘目的:探讨舒尼替尼诱导人肝癌HepG2细胞表达的自然杀伤细胞2族成员D配体(natural killer group 2 member D ligands,NKG2DLs)与核因子kappa B(nuclear factor B kappa,NF-κB)信号通路之间的相互作用。方法:常规体外培养HepG2细胞,利用实时荧光定量PCR检测1μmol/L舒尼替尼处理HepG2细胞24 h前后NF-κB基因家族成员mRNA的表达情况,利用计算机辅助设计并合成NF-κB1、NF-κB2和Rel B siRNA引物,通过脂质体法将目的基因siRNA转染于HepG2细胞,荧光显微镜观察转染情况,实时荧光定量PCR检测干扰效率,Western blotting检测siRNA转染前后He G2细胞内NF-κB1、NF-κB2和Rel B蛋白表达,流式细胞术检测siRNA前后HepG2细胞NKG2DLs表达率。结果:实时荧光定量PCR结果显示,舒尼替尼处理HepG2细胞后,NF-κB1、NF-κB2和Rel B mRNA表达水平升高,主要以NF-κB2 mRNA和Rel B mRNA升高为主。荧光显微镜观测siRNA转染后HepG2细胞红色荧光表达率约为60%,干扰效率达95%以上。siRNA转染后HepG2细胞内NF-κB1、NF-κB2和Rel B蛋白表达水平明显下降,siRNA转染+药物组NKG2DLs表达率明显低于药物处理组(P<0.05)。结论:首次揭示了舒尼替尼通过NF-κB旁路途径诱导肿瘤细胞表达NKG2DLs。
基金National Natural Science Foundation of China(Grant No.81160257)The Science and Technology Project of Ganzhou City(Grant No.GZ2015ZSF072)The Science and Technology Project from the Health and Family Planning Commission of Jiangxi Province(Grant No.20161096)
